NCT06859008
- Conditions
- Chronic Disease, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Disease Attributes, +39 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
Clinical trial condition
Recurrent Grade 3a Follicular Lymphoma
Explore clinical trials studying Recurrent Grade 3a Follicular Lymphoma. Study availability and eligibility vary by location and protocol.
7 public trials
2 recruiting studies
Recurrent Grade 3a Follicular Lymphoma trial results
NCT06453044
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +13 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
- City of Hope Orange County Lennar Foundation Cancer Center Irvine, California, United States
NCT04205409
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +46 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
NCT02568553
- Conditions
- Burkitt Lymphoma, Chronic Disease, DNA Virus Infections, +53 more
- Locations
-
- University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
- City of Hope Comprehensive Cancer Center Duarte, California, United States
- UC San Diego Moores Cancer Center La Jolla, California, United States
- Los Angeles General Medical Center Los Angeles, California, United States
Active, Not Recruiting
Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
NCT02520791
- Conditions
- Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +29 more
- Locations
-
- City of Hope Comprehensive Cancer Center Duarte, California, United States
- University of California Davis Comprehensive Cancer Center Sacramento, California, United States
- Smilow Cancer Center/Yale-New Haven Hospital New Haven, Connecticut, United States
- Yale University New Haven, Connecticut, United States
Active, Not Recruiting
Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
NCT02446457
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +13 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Active, Not Recruiting
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
NCT03150329
- Conditions
- Grade 3b Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +25 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States